ClinicalTrials.gg
TerminatedNCT04479436Updated May 18, 2025Results posted

A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer

A Phase 2 interventional study of Patritumab Deruxtecan in Metastatic Colorectal Cancer, sponsored by Daiichi Sankyo. Terminated at 46 sites in 8 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-05-18.

Sponsored by Daiichi Sankyo · Phase 2, Interventional, and Treatment

Why this study was terminated
Study was terminated early given the Interim Analysis for Part 1 (signal finding) did not meet pre-specified criteria and will not proceed to Part 2. Sponsor will proceed closing the study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Colorectal Neoplasms by Daiichi Sankyo — 1 open to participants now, 1 under way, none of them phase 3. Colorectal Neoplasms · Daiichi Sankyo.

Enrollment
9th of 12
40 · median 85
Started
2020
the only one that year
Phase 2
7 of 14
none open now
Registered
12th of 14
by date

Among the 14 studies in Colorectal Neoplasms by Daiichi Sankyo, this one is the 9th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2020, is one of 7 in phase 2, and was the 12th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 14 studies in Colorectal Neoplasms by Daiichi Sankyo is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Colorectal Neoplasms by Daiichi Sankyo, or all of them as a file.
02

Study summary

This study is designed to primarily evaluate the safety and efficacy of U3-1402 in participants with advanced or metastatic colorectal cancer (CRC) who have received at least 2 prior lines of therapy and will explore clinical benefit according to human epidermal growth factor receptor 3 (HER3) tumor expression level in otherwise refractory tumors.

Read the detailed description

There will be 2 cohorts with enrollment in 2 parts. Participants will be treated on Day 1 of each 21-day cycle (every 3 weeks) with U3-1402 5.6 mg/kg intravenous (IV). The estimated treatment period is approximately 8 months and the follow-up period is approximately 4 months.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • Metastatic Colorectal Cancer
  • U3-1402
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has provided written prior to the start of any study specific procedures.
  • Participants ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is >18 years old).
  • Pathological/histological confirmation of advanced or colon or rectal adenocarcinoma.
  • Must be resistant, , or intolerant to at least 2 , that must include all of the following agents:

    • Fluoropyrimidine
    • Irinotecan
    • Platinum agents (e.g, oxaliplatin)
    • An anti-epidermal growth factor receptor (EGFR) agent, if clinically indicated
    • An anti-VEGF agent, if clinically indicated (eg, bevacizumab)
    • An (eg, microsatellite instability-high [MSI-H] status)
    • A BRAF inhibitor, if clinically indicated (eg, BRAF V600E positive)
  • Has at least 1 confirmed by blinded independent central review (BICR) as per (RECIST) Version (v) 1.1.
  • Willing to provide a required pre-treatment tumor and an additional archival tissue sample for the assessment of HER3 expression levels by immunohistochemistry and exploratory biomarkers, defined as:

    1. Pre-treatment tumor biopsy. Participants may be exempted from the requirement to provide a pre-treatment tumor biopsy if archival tumor tissue was collected within 3 months of screening during or after treatment with the last prior cancer treatment and is of sufficient quantity (2 cores or 20 slides with adequate tumor tissue content).
    2. An additional archival tissue sample collected greater than 3 months prior to screening must be available and of sufficient quantity, as defined above, at the time of screening. If an archival tissue sample (collected greater than 3 months prior to screening) is not available, a subject may be included provided the pre-treatment tumor biopsy is obtained and after discussion and agreement from Sponsor (Medical Monitor or designee).
    3. Consent to provide on-treatment tumor biopsy. When at least 10 treatment tumor biopsies have been collected, the Sponsor will provide written notification of a change to the requirement.
  • performance status (ECOG PS) of 0 or 1.
  • ≥3 months.
  • Has adequate bone marrow reserve and organ function at baseline based on local laboratory data defined as follows within 14 days prior to Cycle 1 Day 1:

    • count: ≥100,000/mm\^3 or ≥100 × 10\^9/L (platelet transfusions are not allowed up to 14 days prior to Cycle 1 Day 1 to meet eligibility)
    • : ≥9.0 g/dL (transfusion and/or growth factor support is allowed)
    • : ≥1500/mm\^3 or ≥1.5 × 10\^9/L
    • Serum creatinine (SCr) OR (CrCl): SCr ≤ 1.5 × (ULN), OR CrCl ≥ 30 mL/min as calculated using the Cockcroft- Gault equation or measured CrCl; confirmation of CrCl is only required when creatinine is >1.5 × ULN
    • /aspartate aminotransferase: ≤3 × ULN (if liver metastases are present, ≤5 × ULN)
    • Total : ≤1.5 × ULN if no liver metastases (\<3 × ULN in the presence of documented Gilbert's syndrome [unconjugated hyperbilirubinemia] or liver metastases)
    • Serum albumin: ≥2.5 g/dL
    • (PT) or PT-international normalized ratio (INR) and activated partial thromboplastin time (aPTT) / partial thromboplastin time (PTT): ≤1.5 × ULN except for subjects on coumarin- derivative anticoagulants or other similar anticoagulant therapy, who must have PT-INR within therapeutic range as deemed appropriate by the Investigator

Exclusion criteria

Exclusion Criteria:

  • Any history of interstitial lung disease (including pulmonary fibrosis or radiation pneumonitis), has current interstitial lung disease (ILD), or is suspected to have such disease by imaging during screening.
  • Clinically severe pulmonary compromise (based on Investigator's assessment) resulting from intercurrent pulmonary illnesses including, but not limited to:

    1. any underlying pulmonary disorder (e.g., pulmonary emboli, severe asthma, severe , restrictive lung disease, pleural effusion)
    2. any , connective tissue or inflammatory disorder with pulmonary involvement (eg, rheumatoid arthritis, Sjögren's syndrome, sarcoidosis)

      • OR prior complete pneumonectomy.
  • Is receiving chronic systemic dosed at >10 mg prednisone or equivalent anti-inflammatory activity or any form of therapy prior to Cycle 1 Day 1. Participants who require use of bronchodilators, inhaled or topical steroids, or local steroid injections may be included in the study.
  • Evidence of .
  • Evidence of clinically active spinal cord compression or
  • Inadequate prior to Cycle 1 Day 1 of U3-1402:

    1. Whole brain radiation therapy \<14 days or stereotactic brain radiation therapy \<7 days;
    2. Any cytotoxic chemotherapy, agent or other anticancer drug(s) from a previous cancer treatment regimen or clinical study \<14 days or 5 half-lives, whichever is longer;
    3. Monoclonal antibodies other than , such as bevacizumab (anti-VEGF) and cetuximab (anti-EGFRs) \<28 days;
    4. Immune checkpoint inhibitor therapy \<21 days;
    5. Major surgery (excluding placement of vascular access) \<4 weeks;
    6. Radiotherapy treatment to >30% of the bone marrow or with a wide field of radiation \<28 days or palliative radiation therapy \<14 days;
    7. Chloroquine/hydroxychloroquine ≤14 days.
  • Prior treatment with an anti-HER3 antibody and/or antibody drug conjugate (ADC) that consists of an exatecan derivative that is any topoisomerase I inhibitor (e.g, trastuzumab deruxtecan).
  • Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to National Cancer Institute (NCI-CTCAE) v5.0 Grade ≤1 or baseline.
  • Had primary other than CRC within 3 years prior to Cycle 1 Day 1, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated.
  • Uncontrolled or significant cardiovascular disease prior to Cycle 1 Day 1.
  • Known and/or infection, such as those with serologic evidence of viral infection within 28 days of Cycle 1 Day 1.

    1. Participants with past or resolved hepatitis B virus (HBV) infection are eligible if:

      • Hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (anti-HBc) positive; OR
      • HBsAg positive and HBV deoxyribonucleic acid (DNA) viral load is documented to be ≤2000 IU/mL in the absence of anti-viral therapy and during the previous 12 weeks prior to the viral load evaluation with normal transaminases values (in the absence of liver ); OR
      • HBsAg positive and HBV DNA viral load is documented to be ≤2000 IU/mL in the absence of anti-viral therapy and during the previous 12 weeks prior to the viral load evaluation for participants with liver metastasis and abnormal transaminases with a result of /ALT \<3 × .
    2. Participants with a history of hepatitis C infection will be eligible for enrollment only if the viral load according to local standards of detection is documented to be below the level of detection in the absence of anti-viral therapy during the previous 12 weeks (ie, sustained viral response according to the local product label but no less than 12 weeks, whichever is longer).
  • Participant with any (HIV) infection.
  • Any evidence of severe or uncontrolled systemic diseases (including active bleeding diatheses, active infection), psychiatric illness/social situations, geographical factors, substance abuse, or other factors which in the Investigator's opinion makes it undesirable for the participant to participate in the study or which would jeopardize compliance with the protocol. Screening for chronic conditions is not required.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Cohort 1: HER3 High (IHC 3+, 2+)

    Cohort 1 participants will have high tumor expression levels of human epidermal receptor 3 (HER3) in a pre-treatment biopsy specimen.

    Drug: Patritumab Deruxtecan

  • Experimental
    Cohort 2: HER3 Low/Negative (IHC 1+, 0)

    Cohort 2 participants will have low or negative tumor expression levels of human epidermal receptor 3 (HER3) expression levels in a pre-treatment biopsy specimen.

    Drug: Patritumab Deruxtecan

Interventions

  • U3-1402 will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.

    Also known as: U3-1402

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) As Assessed By Blinded Independent Central Review (BICR) Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

    ORR defined as the proportion of participants with a best overall response of confirmed complete response (CR) or partial response (PR) as assessed by blinded independent central review. CR was defined as a disappearance of all lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesion based on RECIST v1.1.

    Time frame: From Baseline (Day 0) to data cut off (up to approximately 16.5 months)

Secondary outcomes

  1. Duration of Response (DoR) As Assessed by Blinded Independent Central Review (BICR) and Investigator Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

    DoR defined as the time from the first documented response (CR or PR) to the date of disease progression or death due to any cause. CR was defined as a disappearance of all lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions based on RECIST v1.1.

    Time frame: From Baseline (Day 0) to data cut off (up to approximately 16.5 months)

  2. Objective Response Rate (ORR) As Assessed by Investigator Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

    ORR defined as the proportion of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as assessed by Investigator. CR was defined as a disappearance of all lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesion based on RECIST v1.1.

    Time frame: From Baseline (Day 0) to data cut off (up to approximately 16.5 months)

  3. Disease Control Rate (DCR) by Blinded Independent Central Review (BICR) and Investigator Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

    DCR is defined as the proportion of participants who achieved a confirmed best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD) as assessed by blinded independent central review or by the Investigator. Based on RECIST v1.1, CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions.

    Time frame: From Baseline (Day 0) to data cut off (up to approximately 16.5 months)

  4. Time to Tumor Response (TTR) As Assessed by Blinded Independent Central Review (BICR) and Investigator Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

    TTR defined as the time from the start of study treatment to the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) that is subsequently confirmed by Blinded Independent Central Review or by the Investigator. CR was defined as a disappearance of all lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions based on RECIST v1.1.

    Time frame: From Baseline (Day 0) to data cut off (up to approximately 16.5 months)

  5. Progression-free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) and Investigator Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

    PFS is defined as the time from the start of study treatment to the date of the first documentation of objective PD or death due to any cause, whichever is earlier.

    Time frame: From Baseline (Day 0) to data cut off (up to approximately 16.5 months)

  6. Overall Survival (OS) Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

    OS defined as the time from the start of study treatment to the date of death due to any cause.

    Time frame: From Baseline (Day 0) to data cut off (up to approximately 16.5 months)

  7. Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Other Safety Parameters During the Study

    TEAEs, study-drug related TEAE, serious adverse events (SAE), study-drug related SAE, and adverse events of special interest (eg. interstitial lung disease and elevation of aminotransferases and total bilirubin) were assessed. A TEAE was defined as an AE with a start or worsening date during the on-treatment period. An SAE was an AE that resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event.

    Time frame: From Baseline (Day 0) to data cut off (up to approximately 16.5 months)

  8. Number of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline)

    Blood samples were collected to assess the immunogenicity of U3-1402.

    Time frame: At Baseline, and post-Baseline. Post-Baseline including any of the following timepoints- Cycle 1, Days 1&8; Cycles 2&4 and every 2 cycles thereafter, Day 1 (each cycle, 21 days), and at EOT (~16.5 months).

  9. Number of Participants Who Have Treatment-emergent Anti-Drug Antibody (ADA)

    Blood samples were collected to assess the immunogenicity of U3-1402. Treatment-emergent ADA was defined as participants with a negative ADA status at Baseline who had a positive ADA status post-Baseline (treatment-induced ADA), or participants with a positive ADA status at both Baseline and post-Baseline but with an increase of at least 4-fold in ADA titer from Baseline to post-Baseline (treatment-boosted ADA), or participants who had missing ADA data at Baseline and had a positive ADA status post-Baseline.

    Time frame: At Baseline, and post-Baseline. Post-Baseline including any of the following timepoints- Cycle 1, Days 1&8; Cycles 2&4 and every 2 cycles thereafter, Day 1 (each cycle, 21 days), and at EOT (~16.5 months).

  10. Pharmacokinetic Parameter Maximum Serum Concentration (Cmax) Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

    Serum PK parameter Cmax (antibody drug conjugate \[ADC\], total anti-HER3 antibody, and MAAA-1181a) were assessed in the full PK sampling cohort using noncompartmental methods.

    Time frame: At baseline (-8 hour to 0 hour), pre-infusion, and 15 minutes, 1 hour, 2 hour, 4 hour, and 8 hour post-infusion of Cycle 1 and Cycle 3 (each cycle is 21 days)

  11. Pharmacokinetic Parameter Maximum Serum Concentration (Cmax) of MAAA-1181a Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

    Serum PK parameter Cmax of MAAA-1181a was assessed in the full PK sampling cohort using noncompartmental methods.

    Time frame: At baseline (-8 hour to 0 hour), pre-infusion, and 15 minutes, 1 hour, 2 hour, 4 hour, and 8 hour post-infusion of Cycle 1 and Cycle 3 (each cycle is 21 days)

  12. Pharmacokinetic Parameter Time to Reach Maximum Serum Concentration (Tmax) Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

    Serum PK parameter Tmax (antibody drug conjugate \[ADC\], total anti-HER3 antibody, and MAAA-1181a) were assessed in the full PK sampling cohort using noncompartmental methods.

    Time frame: At baseline (-8 hour to 0 hour), pre-infusion, and 15 minutes, 1 hour, 2 hour, 4 hour, and 8 hour post-infusion of Cycle 1 and Cycle 3 (each cycle is 21 days)

  13. Pharmacokinetic ParameterTrough Serum Concentration (Ctrough) Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

    Serum PK parameter Ctrough (antibody drug conjugate \[ADC\] and total anti-HER3 antibody) were assessed in the full PK sampling cohort using noncompartmental methods.

    Time frame: At baseline (-8 hour to 0 hour), pre-infusion, and 15 minutes, 1 hour, 2 hour, 4 hour, and 8 hour post-infusion of Cycle 1 and Cycle 3 (each cycle is 21 days)

  14. Pharmacokinetic ParameterTrough Serum Concentration (Ctrough) of MAAA-1181a Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

    Serum PK parameter Ctrough of MAAA-1181a was assessed in the full PK sampling cohort using noncompartmental methods.

    Time frame: At baseline (-8 hour to 0 hour), pre-infusion, and 15 minutes, 1 hour, 2 hour, 4 hour, and 8 hour post-infusion of Cycle 1 and Cycle 3 (each cycle is 21 days)

  15. Pharmacokinetic of Area Under the Serum Concentration-Time Curve Up to Last Quantifiable Time (AUClast) and During Dosing Interval (AUCtau) Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

    Serum PK parameter AUC (antibody drug conjugate \[ADC\], total anti-HER3 antibody, and MAAA-1181a) were assessed in the full PK sampling cohort using noncompartmental methods.

    Time frame: At baseline (-8 hour to 0 hour), pre-infusion, and 15 minutes, 1 hour, 2 hour, 4 hour, and 8 hour post-infusion of Cycle 1 and Cycle 3 (each cycle is 21 days)

  16. Pharmacokinetic of Area Under the Serum Concentration-Time Curve Up to Last Quantifiable Time (AUClast) and During Dosing Interval (AUCtau) of MAAA-1181a Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

    Serum PK parameter AUC of MAAA-1181a was assessed in the full PK sampling cohort using noncompartmental methods.

    Time frame: At baseline (-8 hour to 0 hour), pre-infusion, and 15 minutes, 1 hour, 2 hour, 4 hour, and 8 hour post-infusion of Cycle 1 and Cycle 3 (each cycle is 21 days)

07

Results

Posted May 18, 2025

Participant flow

A total of 40 participants who met all inclusion criteria and no exclusion criteria were enrolled in the study at 12 sites. All 40 patients received at least one dose of study drug.

Participant flow — Overall Study
MilestoneCohort 1: HER3 High (IHC 3+, 2+)Cohort 2: HER3 Low/Negative (IHC 1+, 0)
Started391
Completed00
Not completed391
Withdrew: Progressive disease261
Withdrew: Adverse event60
Withdrew: Withdrawal by subject50
Withdrew: Clinical progression10
Withdrew: Physician decision10

Outcome measures

PrimaryObjective Response Rate (ORR) As Assessed By Blinded Independent Central Review (BICR) Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

ORR defined as the proportion of participants with a best overall response of confirmed complete response (CR) or partial response (PR) as assessed by blinded independent central review. CR was defined as a disappearance of all lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesion based on RECIST v1.1.

Time frame:
From Baseline (Day 0) to data cut off (up to approximately 16.5 months)
Reported as:
Count of participants · Participants
Objective Response Rate (ORR) As Assessed By Blinded Independent Central Review (BICR) Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer
ParticipantsCohort 1: HER3 High (IHC 3+, 2+)Cohort 2: HER3 Low/Negative (IHC 1+, 0)
Objective Response Rate (ORR) As Assessed By Blinded Independent Central Review (BICR) Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer20
SecondaryDuration of Response (DoR) As Assessed by Blinded Independent Central Review (BICR) and Investigator Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

DoR defined as the time from the first documented response (CR or PR) to the date of disease progression or death due to any cause. CR was defined as a disappearance of all lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions based on RECIST v1.1.

Time frame:
From Baseline (Day 0) to data cut off (up to approximately 16.5 months)
Reported as:
Median · months
Duration of Response (DoR) As Assessed by Blinded Independent Central Review (BICR) and Investigator Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer
monthsCohort 1: HER3 High (IHC 3+, 2+)
Duration of Response: BICR2.91 (2.79 to 3.02)
Duration of Response: Investigator4.48 (2.56 to 6.41)
SecondaryObjective Response Rate (ORR) As Assessed by Investigator Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

ORR defined as the proportion of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as assessed by Investigator. CR was defined as a disappearance of all lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesion based on RECIST v1.1.

Time frame:
From Baseline (Day 0) to data cut off (up to approximately 16.5 months)
Reported as:
Count of participants · Participants
Objective Response Rate (ORR) As Assessed by Investigator Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer
ParticipantsCohort 1: HER3 High (IHC 3+, 2+)
Objective Response Rate (ORR) As Assessed by Investigator Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer2
SecondaryDisease Control Rate (DCR) by Blinded Independent Central Review (BICR) and Investigator Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

DCR is defined as the proportion of participants who achieved a confirmed best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD) as assessed by blinded independent central review or by the Investigator. Based on RECIST v1.1, CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions.

Time frame:
From Baseline (Day 0) to data cut off (up to approximately 16.5 months)
Reported as:
Count of participants · Participants
Disease Control Rate (DCR) by Blinded Independent Central Review (BICR) and Investigator Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer
ParticipantsCohort 1: HER3 High (IHC 3+, 2+)
Disease control rate (BICR)22
Disease control rate (Investigator)22
SecondaryTime to Tumor Response (TTR) As Assessed by Blinded Independent Central Review (BICR) and Investigator Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

TTR defined as the time from the start of study treatment to the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) that is subsequently confirmed by Blinded Independent Central Review or by the Investigator. CR was defined as a disappearance of all lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions based on RECIST v1.1.

Time frame:
From Baseline (Day 0) to data cut off (up to approximately 16.5 months)
Reported as:
Mean · months
Time to Tumor Response (TTR) As Assessed by Blinded Independent Central Review (BICR) and Investigator Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer
monthsCohort 1: HER3 High (IHC 3+, 2+)
Time to tumor response (BICR)1.99 ± 0.813
Time to tumor response (Investigator)1.53 ± 0.163
SecondaryProgression-free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) and Investigator Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

PFS is defined as the time from the start of study treatment to the date of the first documentation of objective PD or death due to any cause, whichever is earlier.

Time frame:
From Baseline (Day 0) to data cut off (up to approximately 16.5 months)
Reported as:
Median · months
Progression-free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) and Investigator Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer
monthsCohort 1: HER3 High (IHC 3+, 2+)Cohort 2: HER3 Low/Negative (IHC 1+, 0)
Progression-free survival (BICR)2.27 (1.51 to 2.96)5.5
Progression-free survival (Investigator)2.53 (1.64 to 3.71)—
SecondaryOverall Survival (OS) Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

OS defined as the time from the start of study treatment to the date of death due to any cause.

Time frame:
From Baseline (Day 0) to data cut off (up to approximately 16.5 months)
Reported as:
Median · months
Overall Survival (OS) Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer
monthsCohort 1: HER3 High (IHC 3+, 2+)Cohort 2: HER3 Low/Negative (IHC 1+, 0)
Overall Survival (OS) Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer10.58 (5.36 to 12.09)8.9
SecondaryNumber of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Other Safety Parameters During the Study

TEAEs, study-drug related TEAE, serious adverse events (SAE), study-drug related SAE, and adverse events of special interest (eg. interstitial lung disease and elevation of aminotransferases and total bilirubin) were assessed. A TEAE was defined as an AE with a start or worsening date during the on-treatment period. An SAE was an AE that resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event.

Time frame:
From Baseline (Day 0) to data cut off (up to approximately 16.5 months)
Reported as:
Count of participants · Participants
Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Other Safety Parameters During the Study
ParticipantsOverall
Treatment-emergent adverse events (TEAEs)40
Study-drug related TEAE37
Serious TEAE (SAE)17
Study-drug related SAE9
Adverse event of special interest (AESI)2
SecondaryNumber of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline)

Blood samples were collected to assess the immunogenicity of U3-1402.

Time frame:
At Baseline, and post-Baseline. Post-Baseline including any of the following timepoints- Cycle 1, Days 1&8; Cycles 2&4 and every 2 cycles thereafter, Day 1 (each cycle, 21 days), and at EOT (~16.5 months).
Reported as:
Count of participants · Participants
Number of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline)
ParticipantsCohort 1: HER3 High (IHC 3+, 2+)
Baseline: Positive0
Baseline: Negative37
Baseline: Missing2
Post-baseline: Positive0
Post-baseline: Negative38
SecondaryNumber of Participants Who Have Treatment-emergent Anti-Drug Antibody (ADA)

Blood samples were collected to assess the immunogenicity of U3-1402. Treatment-emergent ADA was defined as participants with a negative ADA status at Baseline who had a positive ADA status post-Baseline (treatment-induced ADA), or participants with a positive ADA status at both Baseline and post-Baseline but with an increase of at least 4-fold in ADA titer from Baseline to post-Baseline (treatment-boosted ADA), or participants who had missing ADA data at Baseline and had a positive ADA status post-Baseline.

Time frame:
At Baseline, and post-Baseline. Post-Baseline including any of the following timepoints- Cycle 1, Days 1&8; Cycles 2&4 and every 2 cycles thereafter, Day 1 (each cycle, 21 days), and at EOT (~16.5 months).
Reported as:
Count of participants · Participants
Number of Participants Who Have Treatment-emergent Anti-Drug Antibody (ADA)
ParticipantsCohort 1: HER3 High (IHC 3+, 2+)
Treatment-emergent ADA0
Treatment-induced ADA0
Treatment-boosted ADA0
ADA missing at baseline but positive at post-baseline0
SecondaryPharmacokinetic Parameter Maximum Serum Concentration (Cmax) Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

Serum PK parameter Cmax (antibody drug conjugate \[ADC\], total anti-HER3 antibody, and MAAA-1181a) were assessed in the full PK sampling cohort using noncompartmental methods.

Time frame:
At baseline (-8 hour to 0 hour), pre-infusion, and 15 minutes, 1 hour, 2 hour, 4 hour, and 8 hour post-infusion of Cycle 1 and Cycle 3 (each cycle is 21 days)
Reported as:
Mean · ug/mL
Pharmacokinetic Parameter Maximum Serum Concentration (Cmax) Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer
ug/mLCohort 1: HER3 High (IHC 3+, 2+)
U3-1402: Cycle 1155.67 ± 43.45
U3-1402: Cycle 3159.80 ± 47.94
Total anti-HER3 antibody: Cycle 1154.08 ± 32.82
Total anti-HER3 antibody: Cycle 3153.86 ± 39.31
SecondaryPharmacokinetic Parameter Maximum Serum Concentration (Cmax) of MAAA-1181a Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

Serum PK parameter Cmax of MAAA-1181a was assessed in the full PK sampling cohort using noncompartmental methods.

Time frame:
At baseline (-8 hour to 0 hour), pre-infusion, and 15 minutes, 1 hour, 2 hour, 4 hour, and 8 hour post-infusion of Cycle 1 and Cycle 3 (each cycle is 21 days)
Reported as:
Mean · ng/mL
Pharmacokinetic Parameter Maximum Serum Concentration (Cmax) of MAAA-1181a Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer
ng/mLCohort 1: HER3 High (IHC 3+, 2+)
Cycle 138.09 ± 19.68
Cycle 316.13 ± 9.29
SecondaryPharmacokinetic Parameter Time to Reach Maximum Serum Concentration (Tmax) Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

Serum PK parameter Tmax (antibody drug conjugate \[ADC\], total anti-HER3 antibody, and MAAA-1181a) were assessed in the full PK sampling cohort using noncompartmental methods.

Time frame:
At baseline (-8 hour to 0 hour), pre-infusion, and 15 minutes, 1 hour, 2 hour, 4 hour, and 8 hour post-infusion of Cycle 1 and Cycle 3 (each cycle is 21 days)
Reported as:
Median · hours
Pharmacokinetic Parameter Time to Reach Maximum Serum Concentration (Tmax) Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer
hoursCohort 1: HER3 High (IHC 3+, 2+)
U3-1402: Cycle 12.42 (1.52 to 5.67)
U3-1402: Cycle 34.39 (0.53 to 8.78)
Total anti-HER3 antibody: Cycle 11.72 (1.45 to 505.50)
Total anti-HER3 antibody: Cycle 33.86 (0.53 to 8.78)
MAAA-1181a: Cycle 15.28 (2.57 to 9.47)
MAAA-1181a: Cycle 34.45 (0.65 to 8.33)
SecondaryPharmacokinetic ParameterTrough Serum Concentration (Ctrough) Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

Serum PK parameter Ctrough (antibody drug conjugate \[ADC\] and total anti-HER3 antibody) were assessed in the full PK sampling cohort using noncompartmental methods.

Time frame:
At baseline (-8 hour to 0 hour), pre-infusion, and 15 minutes, 1 hour, 2 hour, 4 hour, and 8 hour post-infusion of Cycle 1 and Cycle 3 (each cycle is 21 days)
Reported as:
Mean · ug/mL
Pharmacokinetic ParameterTrough Serum Concentration (Ctrough) Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer
ug/mLCohort 1: HER3 High (IHC 3+, 2+)
U3-1402: Cycle 17.98 ± 24.20
U3-1402: Cycle 312.76 ± 9.19
Total anti-HER3 antibody: Cycle 18.55 ± 29.61
Total anti-HER3 antibody: Cycle 311.49 ± 9.25
SecondaryPharmacokinetic ParameterTrough Serum Concentration (Ctrough) of MAAA-1181a Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

Serum PK parameter Ctrough of MAAA-1181a was assessed in the full PK sampling cohort using noncompartmental methods.

Time frame:
At baseline (-8 hour to 0 hour), pre-infusion, and 15 minutes, 1 hour, 2 hour, 4 hour, and 8 hour post-infusion of Cycle 1 and Cycle 3 (each cycle is 21 days)
Reported as:
Mean · ng/mL
Pharmacokinetic ParameterTrough Serum Concentration (Ctrough) of MAAA-1181a Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer
ng/mLCohort 1: HER3 High (IHC 3+, 2+)
MAAA-1181a: Cycle 10.49 ± 1.42
MAAA-1181a: Cycle 30.68 ± 0.66
SecondaryPharmacokinetic of Area Under the Serum Concentration-Time Curve Up to Last Quantifiable Time (AUClast) and During Dosing Interval (AUCtau) Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

Serum PK parameter AUC (antibody drug conjugate \[ADC\], total anti-HER3 antibody, and MAAA-1181a) were assessed in the full PK sampling cohort using noncompartmental methods.

Time frame:
At baseline (-8 hour to 0 hour), pre-infusion, and 15 minutes, 1 hour, 2 hour, 4 hour, and 8 hour post-infusion of Cycle 1 and Cycle 3 (each cycle is 21 days)
Reported as:
Mean · day*ug/mL
Pharmacokinetic of Area Under the Serum Concentration-Time Curve Up to Last Quantifiable Time (AUClast) and During Dosing Interval (AUCtau) Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer
day*ug/mLCohort 1: HER3 High (IHC 3+, 2+)
U3-1402, AUClast: Cycle 1562.05 ± 246.93
U3-1402, AUCtau: Cycle 1569.42 ± 191.03
U3-1402, AUCtau: Cycle 31230.44 ± 257.08
Total anti-HER3 antibody, AUClast: Cycle 1590.11 ± 279.67
Total anti-HER3 antibody, AUCtau: Cycle 1596.24 ± 217.23
Total anti-HER3 antibody, AUCtau: Cycle 31104.22 ± 397.93
SecondaryPharmacokinetic of Area Under the Serum Concentration-Time Curve Up to Last Quantifiable Time (AUClast) and During Dosing Interval (AUCtau) of MAAA-1181a Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer

Serum PK parameter AUC of MAAA-1181a was assessed in the full PK sampling cohort using noncompartmental methods.

Time frame:
At baseline (-8 hour to 0 hour), pre-infusion, and 15 minutes, 1 hour, 2 hour, 4 hour, and 8 hour post-infusion of Cycle 1 and Cycle 3 (each cycle is 21 days)
Reported as:
Mean · day*ng/mL
Pharmacokinetic of Area Under the Serum Concentration-Time Curve Up to Last Quantifiable Time (AUClast) and During Dosing Interval (AUCtau) of MAAA-1181a Following Administration of U3-1402 In Participants With Advanced or Metastatic Colorectal Cancer
day*ng/mLCohort 1: HER3 High (IHC 3+, 2+)
AUClast: Cycle 189.96 ± 60.43
AUCtau: Cycle 192.81 ± 58.94
AUCtau: Cycle 378.68 ± 34.60

Adverse events

Collected over Adverse events (AEs) were collected for approximately 16.5 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Overall23/40 (57.5%)17/40 (42.5%)40/40 (100%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventOverall
Disease progressionGeneral disorders3/40
Abdominal painGastrointestinal disorders2/40
Acute kidney injuryRenal and urinary disorders2/40
Febrile neutropeniaBlood and lymphatic system disorders2/40
NauseaGeneral disorders2/40
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/40
AnaemiaBlood and lymphatic system disorders1/40
Biliary obstructionHepatobiliary disorders1/40
Cauda equina syndromeNervous system disorders1/40
Cytomegalovirus infectionInfections and infestations1/40
Most frequent other events
Showing 10 of 48
Most frequent other events
EventOverall
FatigueGeneral disorders24/40
NauseaGastrointestinal disorders23/40
Decreased appetiteMetabolism and nutrition disorders17/40
AnaemiaBlood and lymphatic system disorders15/40
DiarrhoeaGastrointestinal disorders15/40
Neutrophil count decreasedInvestigations14/40
VomitingGastrointestinal disorders13/40
Platelet count decreasedInvestigations13/40
ConstipationGastrointestinal disorders11/40
HypokalaemiaMetabolism and nutrition disorders9/40

Baseline characteristics

Demographic and baseline characteristics were assessed in the Full Analysis Set.

Age, Categorical
Age, Categorical(Participants)Cohort 1: HER3 High (IHC 3+, 2+)Cohort 2: HER3 Low/Negative (IHC 1+, 0)Total
<=18 years000
Between 18 and 65 years30030
>=65 years9110
Age, Continuous
Age, Continuous(years)Cohort 1: HER3 High (IHC 3+, 2+)Cohort 2: HER3 Low/Negative (IHC 1+, 0)Total
Mean57.0 ± 8.646757.3 ± 8.67
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: HER3 High (IHC 3+, 2+)Cohort 2: HER3 Low/Negative (IHC 1+, 0)Total
Female13114
Male26026
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: HER3 High (IHC 3+, 2+)Cohort 2: HER3 Low/Negative (IHC 1+, 0)Total
American Indian or Alaska Native000
Asian10010
Native Hawaiian or Other Pacific Islander000
Black or African American303
White26127
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Cohort 1: HER3 High (IHC 3+, 2+)Cohort 2: HER3 Low/Negative (IHC 1+, 0)Total
United States29130
Japan10010
08

Study locations

46 sites
  • Highlands Oncology
    Fayetteville, Arkansas 72703, United States
  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Northwestern Medical Faculty Foundation NMFF Hematology Oncology
    Chicago, Illinois 60611, United States
  • John Hopkins Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21287, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Mayo Clinic
    Rochester, Minnesota 55902, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • Nebraska Cancer Specialists
    Omaha, Nebraska 68130, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08901, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • West Cancer Center
    Germantown, Tennessee 38138, United States
  • Sarah Cannon
    Nashville, Tennessee 37203, United States
  • Mary Crowley Cancer Research
    Dallas, Texas 75230, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • MD Anderson Cancer Center University of Texas
    Houston, Texas 77030, United States
  • Utah Cancer Specialists
    Salt Lake City, Utah 84106, United States
  • Virgina Cancer Specialists
    Fairfax, Virginia 22031, United States
  • UZ Antwerpen
    Edegem, 2650, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Centre Georges-Franois Leclerc
    Dijon, 21000, France
  • CHU Nantes
    Nantes, 44000, France
  • Hospital St Antoine
    Paris, 75012, France
  • Asst Grande Ospedale Metropolitano Niguarda
    Milano, 20162, Italy
  • Aichi Cancer Center Hospital
    Nagoya-shi, Nagoya-shi, Aichi-ken 464-8681, Japan
  • National Hospital Organization - Osaka National Hospital (ONH)
    Osaka-shi, Osaka-shi, Osaka-fu 540-0006, Japan
  • Kindai University Hospital
    Osaka, Osakasayama Shi 589-8511, Japan
  • National Cancer Center Hospital East
    Chiba, 277-0023, Japan
  • The Cancer Institute Hospital Of JFCR
    Tokyo, 135-8550, Japan
  • Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu
    Ostrów Wielkopolski, Poznan 60-569, Poland
  • Szpital Kliniczny Przemienienia Pańskiego.University Hospital, Chemotherapy Department
    Poznań, Poland
  • M Sklodowska Curie Memorial Cancer Center
    Warszawa, 02-034, Poland
  • M Sklodowska Curie Memorial Cancer Center
    Warszawa, Poland
  • Hospital del Mar - Institut Hospital del Mar d'Investigacions Mediques IMIM
    Barcelona, 08003, Spain
  • VHIO Valle de Hebron Instituto de Oncologia
    Barcelona, 08035, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitario HM Sanchinarro, CIOCC
    Madrid, 28050, Spain
  • Consorci Corporació Sanitària Parc Taulí de Sabadell
    Sabadell, 08208, Spain
  • Hospital Universitario Virgen del Rocio
    Sevilla, 41013, Spain
  • Royal Marsden Hospital NHS
    London, SW3 6JJ, United Kingdom
  • Sarah Cannon Research Institute UK
    London, W1G 6AD, United Kingdom
  • Royal Marsden Hospital NHS
    London, United Kingdom
  • Sarah Cannon
    London, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Feb 2022, 16 months.

Results were first posted in May 2025, 3 years 3 months after primary completion. A results delay was requested in Jan 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2020
First posted
Jul 21, 2020
StartActual
Sep 14, 2020
Primary completionActual
Feb 3, 2022
CompletionActual
Feb 3, 2022
Results delay requested
Jan 10, 2023
Results first posted
May 18, 2025
Last update
May 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04479436
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Jul 21, 2020
Start date
Sep 14, 2020
Primary completion
Feb 3, 2022
Completion
Feb 3, 2022
Results posted
May 18, 2025
Last update
May 18, 2025

Study contacts

Global Clinical Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Patritumab deruxtecan

Start the discussion